90,000 Shares in InMode Ltd. $INMD Purchased by Nano Cap New Millennium Growth Fund L P

Nano Cap New Millennium Growth Fund L P acquired a new position in InMode Ltd. (NASDAQ:INMD) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 90,000 shares of the healthcare company’s stock, valued at approximately $1,322,000. InMode accounts for approximately 1.1% of Nano Cap New Millennium Growth Fund L P’s investment portfolio, making the stock its 26th biggest position. Nano Cap New Millennium Growth Fund L P owned approximately 0.14% of InMode as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Doma Perpetual Capital Management LLC raised its position in shares of InMode by 26.8% during the 3rd quarter. Doma Perpetual Capital Management LLC now owns 2,838,431 shares of the healthcare company’s stock valued at $42,293,000 after acquiring an additional 599,108 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in InMode by 234.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,123,756 shares of the healthcare company’s stock worth $19,935,000 after acquiring an additional 788,157 shares during the last quarter. Cooper Creek Partners Management LLC bought a new position in InMode during the 3rd quarter worth approximately $14,980,000. Ancient Art L.P. bought a new position in InMode during the 3rd quarter worth approximately $14,254,000. Finally, Hotchkis & Wiley Capital Management LLC boosted its stake in InMode by 9.9% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 899,090 shares of the healthcare company’s stock worth $13,396,000 after acquiring an additional 81,170 shares during the last quarter. Institutional investors own 68.04% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on INMD. Robert W. Baird reduced their price objective on shares of InMode from $17.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, May 7th. BTIG Research reaffirmed a “neutral” rating on shares of InMode in a research note on Monday, January 26th. Barclays set a $19.00 price objective on InMode and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of InMode in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $16.00.

InMode Trading Down 1.4%

InMode stock opened at $13.83 on Friday. The company has a market cap of $876.25 million, a P/E ratio of 10.17 and a beta of 1.97. InMode Ltd. has a 1-year low of $12.72 and a 1-year high of $16.74. The company has a fifty day simple moving average of $13.89 and a 200 day simple moving average of $14.24.

InMode (NASDAQ:INMD) last posted its quarterly earnings results on Wednesday, May 6th. The healthcare company reported $0.25 earnings per share for the quarter, missing the consensus estimate of $0.30 by ($0.05). The company had revenue of $82.02 million for the quarter, compared to analyst estimates of $79.84 million. InMode had a return on equity of 13.47% and a net margin of 23.27%.The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the firm earned $0.31 EPS.

InMode Company Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.